Amphastar Pharmaceuticals 3Q 2026: Revenue $207.61M, EPS $0.87 — 10-Q Summary

Amphastar’s third-quarter revenue and earnings increased year over year. Higher BAQSIMI, Primatene MIST and lidocaine sales, new ipratropium bromide sales, and growth in other products outweighed declines in epinephrine and glucagon. Lower general and administrative and research and development exp…